Program
orelabrutinib
Also written as “ICP-022”, “Orelabrutinib” and “ICP-248+Orelabrutinib”.
Its studies are mostly in Lymphoma, Mantle-Cell · Lupus Erythematosus, Systemic · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.
Drug pageOrelabrutinib: every studyAll 95 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InnoCare Pharma | 2511 open or running | phase 3since Oct 1, 2020 | Jun 12, 2017 | Aug 31, 2028phase 3 · NCT06082102 |
| Zenas BioPharma (USA)its history only | 22 open or running | phase 3since Jul 3, 2025 | Jul 3, 2025 | Jun 2030phase 3 · NCT07299019 |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseZenas BioPharma licensed it from InnoCare, for multiple sclerosis worldwide, and other uses outside cancer outside Greater China and Southeast Asia.Announced Oct 8, 2025 · Source: Zenas BioPharma and InnoCare (release), Oct 8, 2025
History and studies of InnoCare Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 11 earlier studies, Jun 12, 2017 to Jun 16, 2020.
- Dec 9, 2019Named orelabrutinibINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ICP-022
- Oct 1, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04578613 · 218 planned · China
- Jan 8, 2021Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT04711148 · 160 enrolled · United States, China, Poland and more
- Sep 15, 2021Phase 3 study in Treatment-naїve Mantle Cell LymphomaNCT05051891 · 3 enrolled · China
- Dec 20, 2021Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05232149 · 30 enrolled · China
- Jan 29, 2022Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT05234684 · 150 planned · China
- Mar 25, 2022Phase 1 study in Healthy PersonNCT05316857 · 36 enrolled · China
- Nov 11, 2022Phase 1 study in Healthy SubjectNCT05660720 · 48 enrolled · China
- Dec 14, 2022Phase 1 study in Hepatic ImpairmentNCT05684653 · 34 planned · China
- Jan 10, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT05688696 · 186 planned · China
- Jan 12, 2023Phase 1 study in Hematologic NeoplasmsNCT05728658 · 191 planned · China
- Jul 11, 2023Phase 2 study in Lymphoma, Mantle-CellNCT05978739 · 40 enrolled · China
- Aug 15, 2023Phase 3 study in Chronic Primary Immune Thrombocytopenia (ITP)NCT06004856 · 195 planned · China
- Oct 8, 2023Phase 3 study in Lymphoma, B-Cell, Marginal ZoneNCT06082102 · 324 planned · China
- Apr 9, 2024Phase 3 study in Lymphoma, Mantle-CellNCT06363994 · 476 planned · China
- Oct 8, 2025Zenas BioPharma licensed it from InnoCareLicenseMultiple sclerosis worldwide, and other uses outside cancer outside Greater China and Southeast Asia · announced · Zenas BioPharma and InnoCare (release)
Ahead
- Aug 31, 2028Primary completion: phase 3 study in Lymphoma, B-Cell, Marginal ZoneNCT06082102
- Jun 25, 2031Primary completion: phase 3 study in Lymphoma, Mantle-CellNCT06363994
TargetBeta
“A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 25 InnoCare Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06363994Lymphoma, Mantle-Cell · China | 3 | Recruiting | Jun 25, 2031 | 476 |
| NCT06082102Lymphoma, B-Cell, Marginal Zone · China | 3 | Recruiting | Aug 31, 2028 | 324 |
| NCT06004856Chronic Primary Immune Thrombocytopenia (ITP) · China | 3 | Recruiting | Dec 31, 2025 | 195 |
| NCT05978739Lymphoma, Mantle-Cell · China | 2 | Completed | Dec 10, 2024 | 40 |
| NCT05728658Hematologic Neoplasms · China | 1 | Recruiting | Aug 30, 2025 | 191 |
| NCT05688696Lupus Erythematosus, Systemic · China | 2 | Recruiting | Aug 25, 2025 | 186 |
| NCT05684653Hepatic Impairment · China | 1 | Recruiting | Dec 30, 2023 | 34 |
| NCT05660720Healthy Subject · China | 1 | UNKNOWN | Jun 30, 2023 | 48 |
| NCT05316857Healthy Person · China | 1 | Completed | Jan 4, 2022 | 36 |
| NCT05234684Lymphoma, Large B-Cell, Diffuse · China | 3 | Recruiting | Jul 30, 2024 | 150 |
| NCT05232149Purpura, Thrombocytopenic, Idiopathic · China | 2 | UNKNOWN | Dec 30, 2023 | 30 |
| NCT05051891Treatment-naїve Mantle Cell Lymphoma · China | 3 | Completed | Jun 30, 2025 | 3 |
| NCT04711148Multiple Sclerosis, Relapsing-Remitting · United States, China, Poland and more | 2 | Active, not recruiting | Feb 25, 2026 | 160 |
| NCT04578613Leukemia, Lymphocytic, Chronic, B-Cell · China | 3 | Recruiting | Dec 30, 2024 | 218 |
| NCT04441450Healthy Volunteers · China | – | Completed | Aug 6, 2019 | 6 |
| NCT04440059Waldenstrom's Macroglobulinemia Recurrent · China | 2 | Completed | Jan 9, 2024 | 47 |
| NCT04438044Recurrence · China | 2 | UNKNOWN | Dec 31, 2023 | 61 |
| NCT04438005Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Nov 5, 2021 | 3 |
| NCT04305197Lupus Erythematosus, Systemic · China | 2 | Completed | Apr 28, 2022 | 60 |
| NCT04304040B-cell Lymphoma Recurrent · China | 2 | Active, not recruiting | Dec 30, 2025 | 43 |
| NCT04014205Part 1:r/r B-cell Malignancies · United States, Israel, Poland and more | 2 | Active, not recruiting | Jun 30, 2026 | 81 |
| NCT03797456MZL · China | 2 | Completed | Dec 27, 2023 | 111 |
| NCT03494179Lymphoma, Mantle-Cell · China | 2 | Completed | Apr 10, 2020 | 106 |
| NCT03493217CLL/SLL · China | 2 | UNKNOWN | Dec 31, 2022 | 100 |
| NCT03189017Lupus Erythematosus, Systemic · Australia | 1 | Completed | Feb 5, 2018 | 64 |
How it is read
Names in the registry
- “ICP-022”, 11 entries
- “Orelabrutinib”, 7 entries
- “ICP-248+Orelabrutinib”, 3 entries
- “Orelabrutinib High dose”, 1 entry
- “Orelabrutinib Low dose”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 4 studies
- Lupus Erythematosus, Systemic, 3 studies
- Multiple Sclerosis, Chronic Progressive, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.